Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01485029
Other study ID # 11-APN-01
Secondary ID
Status Recruiting
Phase N/A
First received September 23, 2011
Last updated December 17, 2012
Start date January 2012
Est. completion date January 2013

Study information

Verified date December 2011
Source Centre Hospitalier Universitaire de Nice
Contact Christian PRADIER, PU-PH
Email pradier.c@chu-nice.fr
Is FDA regulated No
Health authority France: Committee for the Protection of PersonnesFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

Antibiotic consumption and antimicrobial resistance remain notoriously high in France, particularly among children below three years of age. In France, the pneumococcal conjugate vaccine was officially recommended for all children under two in 2003, and consequently changes occurred in Streptococcus pneumoniae serotype distribution. Bacterial carriage among children attending day-care centres may result from vaccine- and antibiotic-driven selective pressure with possible repercussions on the community.


Description:

Antibiotic consumption and antimicrobial resistance remain notoriously high in France, particularly among children below three years of age. In France, the pneumococcal conjugate vaccine was officially recommended for all children under two in 2003, and consequently changes occurred in Streptococcus pneumoniae serotype distribution. Bacterial carriage among children attending day-care centres may result from vaccine- and antibiotic-driven selective pressure with possible repercussions on the community.

To identify prevalence (rates) and trends in antibiotic resistance patterns in Streptococcus pneumoniae (SP) among children attending day-care centres, as well as antibiotic prescriptions and vaccine rates, nasopharyngeal (NP) carriage was monitored, by conducting five cross-sectional surveys from January to March 1999, 2002, 2004, 2006 and 2008 among these children in the area of the Alpes Maritimes, in South-Eastern France.

Interventions promoting prudent antibiotic use (PAU) took place in 2000 and since 2003, with temporary effectiveness but national prescription rates are reported to be currently increasing again. A new pneumococcal conjugate vaccine covering more serotypes (13-valent) now replaces the previous one. In this situation, a new cross-sectional survey in day-care centres with the same design may answer the following questions.

- Increasing antibiotic susceptibility was observed during past successive surveys. Has this trend been sustained to this day?

- Are antibiotics prescription rates among children attending day-care centres still decreasing, have they stabilized, or are they on the rise again reflecting recently reported national trends?

- Regarding choice of antimicrobial treatment, are 3rd generation cephalosporin increasingly prescribed rather than aminopenicillins?

- Is implementation of the new wider spectrum pneumococcal conjugate vaccine exerting changes on serotype distribution and thus on the nasopharyngeal ecosystem of these children? These parameters will be useful to renew, or even reinforce, and adapt professional guidelines and community-oriented messages concerning prudent antibiotic use.

Sub-study: Antibiotic-resistant enterobacteriaceae, initially observed in the hospital setting, are currently spreading within the community, especially extended-spectrum beta-lactamase-producing enterobacteriaceae, threatening antibiotic effectiveness in case of infection. Such infections with Enterobacteriaceae, in particular urinary tract infections, can occur among children. Prevalence rates of such carriage among children attending day-care centres is unknown, although they are highly exposed to antibiotics in relation with frequent respiratory tract infections, in particular to 3rd generation cephalosporins. To assess this prevalence rate, faecal samples from children attending day-care centres will be collected during the cross-sectional nasopharyngeal survey quoted above.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date January 2013
Est. primary completion date April 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 3 Months to 4 Years
Eligibility Inclusion Criteria:

- Children aged from 3 months to 4 years

- Attending a day care center

- Parents give informed consent

Exclusion Criteria:

- parents refusal

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Procedure:
Nasopharyngeal (NP) aspirate
Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs

Locations

Country Name City State
France Hôpital Archet 1 Nice

Sponsors (1)

Lead Sponsor Collaborator
Department of Clinical Research and Innovation

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Streptococcus pneumoniae nasopharyngeal carriage among children attending day-care centres, and Streptococcus pneumoniae antibiotic susceptibility Substudy: Enterobacterial intestinal carriage and susceptibility to 3rd generation cephalosporins one day No
Secondary •Antibiotics prescriptions within the 3 previous months in children's health booklets and in a questionnaire completed by parents one day No
Secondary • Immunization status for pneumococcal conjugate vaccine PCV7-type vaccine from children's health books and from day care centres health files one day No
Secondary • Pneumococcal serotypes distribution compared to immunization status one day No
Secondary • Comparison of the data above with the previous five cross-sectional surveys one day No
See also
  Status Clinical Trial Phase
Completed NCT02580123 - Smile-Kids: Study on Complementary Feeding Transition N/A